Mellar Davis

Taussig cancer center, The Harry R Horvitz Center for Palliative Medicine, Cleveland Clinic Foundation, United States of America

Dr Mellar is a staff physician at the Cleveland Clinic Foundation, Ohio, and also the Director of Research at the Harry R. Horvitz Centre for Palliative Medicine. Dr Mellar received his medical degree from Ohio State University, College of Medicine. His internal medicine residency was at Riverside Methodist Hospital, Columbus, Ohio, and his fellowship was performed at the Mayo Clinic, Rochester, MN.

Dr Mellar is the recipient of the Compassion in Medicine Achievement Award from Riverside Methodist Hospital and the Special Achievement, Alumni Award from Otterbein College, Ohio. In 2001 he was a nominee for the Governers Community Service from the Chest Foundation.

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Oncology > Supportive & Palliative Cancer Care (since 25 October 2007)

All recent recommendations

• 4.8
  Missed opportunities for interval empathy in lung cancer communication.
  Recommended by Toby Campbell, Mellar Davis
  
• 4.9
  Cancer and the risk of suicide in older americans.
  Recommended by Elizabeth Gore, Lodovico Balducci, Mellar Davis
  
• 3.2
  Aggressiveness of care in a prospective cohort of patients with advanced NSCLC.
  Recommended by Marcin Chwistek, Mellar Davis
  
• 3.2
  Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain.
  Recommended by Gyongyi Horvath, Mellar Davis
  
• 3.2
  Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats.
  Recommended by Michael Fehlings with James Austin, Mellar Davis
  
• 3.2
  A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
  Recommended by Victor Chang, Mellar Davis
  
• 4.8
  Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis.
  Recommended by David Karp, Davis Mellar
  
• 4.8
  Methylnaltrexone for opioid-induced constipation in advanced illness.
  Recommended by Peter Conzen with Daniel Chappell, Davis Mellar
  
• 6.4
  The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus.
  Recommended by Stephan Schug, Davis Mellar
  
• 6.8
  Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome.
  Recommended by Chris Del Mar, Klaus Bielefeldt, Roberto De Giorgio, Davis Mellar, Mike Cummings
  
• 6.4
  Gabapentin: a multimodal perioperative drug?
  Recommended by Michael Serpell, Davis Mellar
  
• 6.4
  Reassurance: help or hinder in the treatment of pain.
  Recommended by Rona Levy, Davis Mellar
  
• 4.8
  Association of ABCB1/MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief.
  Recommended by Albert Dahan with Dr Elise Sarton , Davis Mellar
  
• 3.2
  Opioid medications and longitudinal risk of delirium in hospitalized cancer patients.
  Recommended by Michael Fisch, Davis Mellar
  
• 3.2
  Cancer pain and its impact on diagnosis, survival and quality of life.
  Recommended by Andrew Wilcock, Mellar Davis
  
• 4.8
  Individual differences in reward responding explain placebo-induced expectations and effects.
  Recommended by Howard Fields, Davis Mellar